Recently, the antinociceptive and anti-inflammatory efficacy of bee venom (BV, Apis mellifera) has been confirmed in rodent models of inflammation and arthritis. Interestingly, the antinociceptive and anti-inflammatory effect of whole BV can be reproduced by two water-soluble fractions of BV (>20 kDa:BVAF1 and<10 kDa: BVAF3). Based on these scientific findings, BV and its effective water-soluble fractions have been proposed as potential anti-inflammatory and antinociceptive pharmaceuticals. While BV's anti-inflammatory and antinociceptive properties have been well documented, there have been no careful studies of potential, side effects of BV and its fractions when administered in the therapeutic range (BV, 5 microgram/kg; BVAF1, 0.2 microgram/kg: BVAF3, 3 microgram/kg; subcutaneous or intradermal). Such information is critical for future clinical use of BV in humans. Because of this paucity of information, the present study was designed to determine the general pharmacological/physiological effects of BV and its fractions administration on the rodent central nervous, cardiovascular, respiratory and gastrointestinal system. Subcutaneous BV and its fractions treatment did not produce any significant effects on general physiological functions at the highest dose tested (200-fold and 100-fold doses higher than that used clinically, respectively) except writhing test. These results demonstrate that doses of BV or BV subfractions in the therapeutic range or higher can be used as safe antinociceptive and anti-inflammatory agents.
Analgesics/*pharmacology ; Animals ; Anti-Inflammatory Agents/*pharmacology ; Bee Venoms/*pharmacology ; Cardiovascular System/*drug effects ; Central Nervous System/*drug effects ; Digestive System/*drug effects ; Male ; Mice ; Mice, Inbred ICR ; Rabbits ; Rats ; Rats, Sprague-Dawley ; Respiratory System/*drug effects

The precise relationship between the degree of pain and the degree of inflammation in the individual remains debated. A quantitative analysis simultaneously applied to the immediate and prolonged painful consequences of inflammation has not yet been done. Thus, the correlations between edema, nociception and hypersensitivity following an inflammatory insult were assessed in rodents. To better understand the therapeutic value of modifying specific aspects of inflammation, the effects of an anti-inflammatory drug were compared to the results. Inbred strains of mice and outbred rats received an intraplantar injection of honeybee venom and the between-group and within-group correlations were calculated for spontaneous nociceptive measures, thermal and mechanical hypersensitivity, and edema and temperature. The effect of indomethacin on the pain and inflammation measures was examined. Edema correlated with spontaneous flinching, licking and lifting of the injected paw (P< or =0.003), and not with thermal or mechanical hypersensitivity. Indomethacin affected edema and spontaneous nociception dose-dependently, and affected hypersensitivity only at the highest dose tested (P< 0.05). These results suggest that edema may contribute only to immediate spontaneous nociceptive responses to an inflammatory insult, and not to the more clinically relevant prolonged hypersensitivity. This analysis represents a method for determining which inflammatory processes are the most promising therapeutic targets against the multiple painful consequences of inflammation.
Animals ; Anti-Inflammatory Agents, Non-Steroidal ; pharmacology ; Bee Venoms ; Edema ; chemically induced ; complications ; Indomethacin ; pharmacology ; Inflammation ; chemically induced ; complications ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Nociceptors ; physiology ; Pain ; etiology ; physiopathology ; Pain Measurement ; Rats ; Rats, Sprague-Dawley

Nociceptin is an endogenous ligand for the opioid receptor-like 1 (ORL1) receptor. The present study was designed to investigate spinal actions of nociceptin on the spontaneous nociception, hyperalgesia and inflammation induced by subcutaneous bee venom injection. Subcutaneous injection of bee venom into one hindpaw of conscious rat produced a persistent spontaneous nociception followed by a long-lasting primary heat and mechanical hyperalgesia as well as local inflammation. Compared with the pre-saline group, pretreatment with intrathecal injection of three doses (3, 10 and 30 nmol) of nociceptin produced significant suppression on the spontaneous paw flinching reflex. The inhibitory rates were 37+/-7, 43+/-6 and 57+/-11%, respectively, which were enhanced with an increase in the concentration of nociceptin. The inhibitory action of nociceptin was completely antagonized by a new selective ORL1 receptor antagonist CompB (30 nmol). Pre-treatment with 10 nmol nociceptin prior to bee venom produced no significant effect on the occurrence of primary heat and mechanical hyperalgesia, nor did post-treatment with the same dose again 3 h after bee venom injection. Additionally, pre-treatment with nociceptin had no effect on the bee venom-induced increase in paw thickness and volume and the plasma protein extravasation. These results indicate that intrathecal nociceptin has no effect on primary heat and mechanical hyperalgesia as well as inflammation, but has dose-related anti-nociceptive effect on the bee venom-induced persistent spontaneous nociception via activation of spinal ORL1 receptor.
Analgesics ; pharmacology ; Animals ; Bee Venoms ; Hyperalgesia ; chemically induced ; physiopathology ; Inflammation ; chemically induced ; physiopathology ; Injections, Spinal ; Injections, Subcutaneous ; Male ; Nociceptors ; physiopathology ; Opioid Peptides ; pharmacology ; Pain ; chemically induced ; physiopathology ; Rats ; Rats, Sprague-Dawley

Recently the use of peptides in bee venom (PBV) for cancer therapy has attracted considerable attention. In this study, the sterically stabilized liposomal PBV (PBV-SL) was prepared using soybean phosphatidylcholine, cholesterol, and cholesterol-PEG-COOH. The humanized antihepatoma disulfide-stabilized Fv (hdscFv25) was coupled to sterically stabilized liposomes using the N-hydroxysuccinimide ester method. The hdscFv25-immunoliposomes (SIL[hdscFv25]) were immunoreactive as determined by ELISA assay. SIL[hdscFv25] showed higher tumor cells selectivity. PBV-SIL[hdscFv25] can kill SMMC-7721 cells in vitro with higher efficiency than non-targeted liposomes. Whereas cytotoxicties were compared for Hela cells, no significant differences was observed between PBV-SIL[hdscFv25] and PBV-SL. Sterically stabilized immunoliposomal peptides in bee venom could be one drug targeting delivery system.
Antineoplastic Agents ; administration & dosage ; pharmacology ; Bee Venoms ; chemistry ; Carcinoma, Hepatocellular ; pathology ; Cell Line, Tumor ; Cell Survival ; drug effects ; Cholesterol ; chemistry ; Drug Delivery Systems ; HeLa Cells ; Humans ; Immunoconjugates ; chemistry ; pharmacology ; Liposomes ; chemistry ; Liver Neoplasms ; pathology ; Melitten ; administration & dosage ; isolation & purification ; pharmacology ; Peptides ; administration & dosage ; isolation & purification ; pharmacology ; Recombinant Proteins ; administration & dosage ; pharmacology

To study whether commercial traditional Chinese medicinal preparations Injection Paederiae (IP) or Injection Stauntonia (IS) has anti-nociceptive and/or anti-inflammatory effects, we used two persistent pain models (bee venom and formalin test) to evaluate the systemic effects of IP or IS on the chemical tissue injury-induced persistent spontaneous pain-related responses (PSPR), primary thermal/mechanical hyperalgesia and inflammation in conscious rats. Injection of bee venom (BV, 0.1 mg, 50 microl) into the plantar surface of one hind paw resulted in not only a 1-h monophasic PSPR such as flinching reflex in the injected paw and a subsequent period of 3-4 days primary heat and mechanical hyperalgesia, but also a marked sign of inflammation, including redness and swelling of the plantar surface in the injected paw. Intraplantar injection of formalin produced two phases of PSPR as reported previously. Systemic pre-treatment with three doses of IP (0.32, 1.6 and 9.0 ml/kg, 500%) or IS (0.32, 1.6 and 9.0 ml/kg, 250%) produced a dose-dependent suppression of the BV- or formalin-induced flinching reflex of 1 h time course as compared with the saline control group. Post-treatment with IP or IS 5 min after BV injection also produced a significant suppression of the flinching reflex in both BV test and formalin test respectively, as compared with the control group. However, neither pre- nor post-treatment with IP or IS produced any significantly suppressive effect on the BV-induced primary heat and mechanical hyperalgesia and inflammation. The analgesia produced by IP or IS was not mediated by the endogenous opioid receptors since naloxone, a non-selective opioid receptor antagonist, had no reversal effect on the IP and IS-produced analgesia in the BV-induced PSPR. Our present results suggest that IP or IS might prevent and relieve clinical persistent spontaneous pain, but without any anti-nociceptive and anti-inflammatory effects on the primary heat hyperalgesia, mechanical hyperalgesia, as well as inflammatory responses. The BV test might be a useful model of pain to evaluate and screen anti-nociceptive and anti-inflammatory effects of certain compounds of the Chinese medicinal herbs on the pathological origins of pain.
Analgesics ; pharmacology ; Animals ; Bee Venoms ; Drugs, Chinese Herbal ; pharmacology ; Female ; Formaldehyde ; Hyperalgesia ; physiopathology ; Inflammation ; chemically induced ; physiopathology ; Injections, Intravenous ; Male ; Nociceptors ; drug effects ; Pain ; chemically induced ; physiopathology ; Pain Threshold ; drug effects ; Pyrans ; pharmacology ; Rats ; Rats, Sprague-Dawley ; Saponins ; pharmacology ; Steroids ; pharmacology

To confirm whether class I histone deacetylase inhibitors (HDACIs) are effective in relief of peripheral inflammatory pain, the effects of two selective inhibitors, MS-275 and MGCD0103, were studied in rats inflamed by subcutaneous (s.c.) injection of bee venom (BV). The BV test is characterized by displaying both persistent spontaneous nociception (PSN) and primary hypersensitivity. Intrathecal (i.t.) pre-treatment of either MS-275 or MGCD0103 with a single dose of 60 nmol/20 μL resulted in profound suppression of both PSN and primary thermal hypersensitivity but without significant influence upon the primary mechanical hypersensitivity and mirror-image thermal hypersensitivity. Moreover, the up-regulation of both HDAC1 and HDAC2 induced by s.c. BV injection was completely suppressed by i.t. pre-treatment of MS-275. The present results provide with another new line of evidence showing involvement of epigenetic regulation of chromatin structure by HDAC1/2-mediated histone hypoacetylation in the BV-induced PSN and thermal hypersensitivity and demonstrate the beneficial effects of class I HDACIs in prevention of peripheral inflammatory pain from occurring.
Animals ; Bee Venoms ; administration & dosage ; Benzamides ; pharmacology ; Epigenesis, Genetic ; Histone Deacetylase 1 ; genetics ; metabolism ; Histone Deacetylase 2 ; genetics ; metabolism ; Histone Deacetylase Inhibitors ; pharmacology ; Hot Temperature ; Hyperalgesia ; drug therapy ; Inflammation ; drug therapy ; Injections, Subcutaneous ; Nociception ; Pain ; chemically induced ; drug therapy ; Pain Measurement ; Pyridines ; pharmacology ; Pyrimidines ; pharmacology ; Rats ; Rats, Sprague-Dawley ; Up-Regulation

To investigate whether BCG, lymphtoxin (LT) or bee venom (BV) can prevent insulitis and development of diabetes in non-obese diabetic (NOD) mice, we measured the degree of insulitis and incidence of diabetes in 24 ICR and 96 female NOD mice. NOD mice were randomly assigned to control, BCG-, LT-, and BV-treated groups. The BCG was given once at 6 weeks of age, and LT was given in 3 weekly doses from the age of 4 to 10 weeks. The BV was injected in 2 weekly doses from the age of 4 to 10 weeks. Diabetes started in control group at 18 weeks of age, in BCG group at 24 weeks of age, and in LT- or BV-treated group at 23 weeks of age. Cumulative incidences of diabetes at 25 weeks of age in control, BCG-, LT-, and BV-treated NOD mice are 58, 17, 25, and 21%, respectively. Incidence and severity of insulitis were reduced by BCG, LT and BV treatment. In conclusion, these results suggest that BCG, LT or BV treatment in NOD mice at early age inhibit insulitis, onset and cumulative incidence of diabetes.
Adjuvants, Immunologic/pharmacology* ; Age Factors ; Animal ; Bee Venoms/pharmacology* ; Cholesterol/blood ; Diabetes Mellitus/prevention & control* ; Diabetes Mellitus/immunology ; Diabetes Mellitus, Insulin-Dependent/prevention & control* ; Diabetes Mellitus, Insulin-Dependent/immunology ; Disease Models, Animal ; Female ; Islets of Langerhans/pathology* ; Islets of Langerhans/drug effects ; Lymphotoxin/pharmacology* ; Mice ; Mice, Inbred NOD ; Mycobacterium bovis/immunology* ; Triglycerides/blood

OBJECTIVETo investigate the therapeutic effect of acupoint injection of bee venom on collagen-induced arthritis (CIA) in rats and explore the mechanism of bee venom therapy in the treatment of rheumatoid arthritis.

METHODSFifteen male Wistar rats were randomly divided into bee venom treatment group (BV group), CIA model group, and control group. In the former two groups, CIA was induced by injections of collagen II+IFA (0.2 mL) via the tail vein, and in the control group, normal saline was injected instead. The rats in BV group received daily injection of 0.1 mL (3 mg/mL) bee venom for 7 consecutive days. All the rats were assessed for paw thickness and arthritis index from days 14 to 21, and the pain threshold was determined on day 21. The expressions of TRPV1 and TrkA in the dorsal root ganglion at the level of L4-6 were detected using immunohistochemistry and Western blotting, respectively.

RESULTSThe rats in CIA model group started to show paw swelling on day 10, and by day 14, all the rats in this group showed typical signs of CIA. In BV group, the rats receiving been venom therapy for 7 days showed a significantly smaller paw thickness and a low arthritis index than those in the model group. The pain threshold was the highest in the control group and the lowest in the model group. TRPV1-positive cells and TrkA expression in the dorsal root ganglion was significantly reduced in BV group as compared with that in the model group.

CONCLUSIONs Injection of bee venom can decrease expression of TRPV1 and TrkA in the dorsal root ganglion to produce anti-inflammatory and analgesic effects, suggesting the potential value of bee venom in the treatment of rheumatoid arthritis.

Analgesics ; pharmacology ; Animals ; Anti-Inflammatory Agents ; pharmacology ; Arthritis, Experimental ; chemically induced ; drug therapy ; Arthritis, Rheumatoid ; drug therapy ; Bee Venoms ; pharmacology ; Collagen ; Edema ; Ganglia, Spinal ; drug effects ; metabolism ; Injections ; Male ; Pain Threshold ; Random Allocation ; Rats ; Rats, Wistar ; Receptor, trkA ; metabolism ; TRPV Cation Channels ; metabolism

Pigmentation may result from melanocyte proliferation, melanogenesis, migration or increases in dendricity. Recently, it has been reported that secreted phospholipase A2(sPLA2) known as a component of bee venom (BV), stimulates melanocyte dendricity and pigmentation. BV has been used clinically to control rheumatoid arthritis and to ameliorate pain via its anti-inflammatory and antinociceptive properties. Moreover, after treatment with BV, pigmentation around the injection sites was occasionally observed and the pigmentation lasted a few months. However, no study has been done about the effect of BV on melanocytes. Thus, in the present study, we examined the effect of BV on the proliferation, melanogenesis, dendricity and migration in normal human melanocytes and its signal transduction. BV increased the number of melanocytes dose and time dependently through PKA, ERK, and PI3K/Akt activation. The level of cAMP was also increased by BV treatment. Moreover, BV induced melanogenesis through increased tyrosinase expression. Furthermore, BV induced melanocyte dendricity and migration through PLA2activation. Overall, in this study, we demonstrated that BV may have an effect on the melanocyte proliferation, melanogenesis, dendricity and migration through complex signaling pathways in vitro, responsible for the pigmentation. Thus, our study suggests a possibility that BV may be developed as a therapeutic drug for inducing repigmentation in vitiligo skin.
Animals ; Base Sequence ; Bee Venoms/*pharmacology ; Cell Movement/drug effects ; Cell Proliferation/drug effects ; Cells, Cultured ; Cyclic AMP/metabolism ; DNA Primers/genetics ; Forskolin/pharmacology ; Gene Expression/drug effects ; Humans ; Melanins/biosynthesis ; Melanocytes/cytology/*drug effects/physiology ; Microphthalmia-Associated Transcription Factor/biosynthesis/genetics ; Monophenol Monooxygenase/biosynthesis/genetics ; Signal Transduction/drug effects